Journal
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Volume 34, Issue 2, Pages 137-141Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MEG.0000000000002013
Keywords
COVID-19; gastrointestinal symptoms; mortality; outcomes; proton pump inhibitors; SARS-CoV-2
Categories
Ask authors/readers for more resources
Reduced gastric acid caused by proton pump inhibitors may predispose COVID-19 patients to severe infections and increase mortality risk.
Introduction Severe acute respiratory syndrome coronavirus-2 may escape the inactivation by gastric acid because of hypochlorhydria caused by proton pump inhibitors (PPIs), which could predispose the patients to severe COVID-19. Methods We studied the association between prehospitalization PPI exposure and clinical outcomes among hospitalized COVID-19 patients. Results A total of 295 hospitalized COVID-19 patients were included in the study. 15.6% of hospitalized COVID-19 patients were on PPIs at home. Mortality among PPI-users was 2.3 times higher than non-users, along with 2.3 times higher risk of acute respiratory distress syndrome after adjusting for confounding variables. Conclusion We found that prehospitalization PPI-exposure is independently associated with worse clinical outcomes, including mortality in COVID-19 patients, regardless of the presence of cardiovascular comorbidities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available